Zobrazeno 1 - 10
of 334
pro vyhledávání: '"Soo-Taek Uh"'
Autor:
Hee-Young Yoon, Soo-Taek Uh
Publikováno v:
Tuberculosis and Respiratory Diseases, Vol 85, Iss 4, Pp 320-331 (2022)
Coronavirus disease 2019 (COVID-19) has become a major health burden worldwide, with over 450 million confirmed cases and 6 million deaths. Although the acute phase of COVID-19 management has been established, there is still a long way to go to evalu
Externí odkaz:
https://doaj.org/article/1af8c9f36abc4b7fbf417861c0776c19
Autor:
Joonyong Jang, So-My Koo, Ki-Up Kim, Yang-Ki Kim, Soo-taek Uh, Gae-Eil Jang, Wonho Chang, Bo Young Lee
Publikováno v:
Tuberculosis and Respiratory Diseases, Vol 85, Iss 3, Pp 249-255 (2022)
Background The main cause of death in pulmonary embolism (PE) is right-heart failure due to acute pressure overload. In this sense, extracorporeal membrane oxygenation (ECMO) might be useful in maintaining hemodynamic stability and improving organ pe
Externí odkaz:
https://doaj.org/article/7285bf8e54fd4008906eb5bb53a4459b
Autor:
Yangjin Jegal, Jong Sun Park, Song Yee Kim, Hongseok Yoo, Sung Hwan Jeong, Jin Woo Song, Jae Ha Lee, Hong Lyeol Lee, Sun Mi Choi, Young Whan Kim, Yong Hyun Kim, Hye Sook Choi, Jongmin Lee, Soo-Taek Uh, Tae-Hyung Kim, Sang-Heon Kim, Won-Yeon Lee, Yee Hyung Kim, Hyun-kyung Lee, Eun Joo Lee, Eun Young Heo, Sei Hoon Yang, Hyung Koo Kang, Man Pyo Chung
Publikováno v:
Tuberculosis and Respiratory Diseases, Vol 85, Iss 2, Pp 185-194 (2022)
Background The Korea Interstitial Lung Disease Study Group has made a new nationwide idiopathic pulmonary fibrosis (IPF) registry because the routine clinical practice has changed due to new guidelines and newly developed antifibrotic agents in the r
Externí odkaz:
https://doaj.org/article/df3157d820ed46cd92db459cf1e09ffb
Autor:
Jae Ha Lee, Ji Hoon Jang, Hang-Jea Jang, Song Yee Kim, Man Pyo Chung, Hongseok Yoo, Sung Hwan Jeong, Jin Woo Song, Hong Lyeol Lee, Sun Mi Choi, Young Whan Kim, Yong Hyun Kim, Sung Woo Park, Jong Sun Park, Yangin Jegal, Jongmin Lee, Soo-Taek Uh, Tae-Hyung Kim, Yee Hyung Kim, Beomsu Shin, Hyun-kyung Lee, Sei-Hoon Yang, Hyun Lee, Sang-Heon Kim, Eun-Joo Lee, Hye Sook Choi, Hyung Koo Kang, Eun Young Heo, Won-Yeon Lee, Moo Suk Park
Publikováno v:
Frontiers in Medicine, Vol 10 (2023)
BackgroundIdiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung disease (ILD) with variable and heterogeneous clinical course. The GAP (gender, age, and physiology) model had been used to predict mortality in patients with
Externí odkaz:
https://doaj.org/article/575f8cb656a040feb4f72bbe0b5380ea
Autor:
Sang Hoon Lee, M.D., Yoomi Yeo, M.D., Tae-Hyung Kim, M.D., Ph.D., Hong Lyeol Lee, M.D., Ph.D., Jin Hwa Lee, M.D., Ph.D., Yong Bum Park, M.D., Jong Sun Park, M.D., Ph.D., Yee Hyung Kim, M.D., Ph.D., Jin Woo Song, M.D., Ph.D., Byung Woo Jhun, M.D., Ph.D., Hyun Jung Kim, M.D., Ph.D., Jinkyeong Park, M.D., Ph.D., Soo-Taek Uh, M.D., Ph.D., Young Whan Kim, M.D., Ph.D., Dong Soon Kim, M.D., Ph.D., Moo Suk Park, M.D., Ph.D., on behalf of Korean Interstitial Lung Diseases Study Group
Publikováno v:
Tuberculosis and Respiratory Diseases, Vol 82, Iss 2, Pp 102-117 (2019)
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia, which presents with a progressive worsening dyspnea, and thus a poor outcome. The members of the Korean Academy of Tuberculosis and Respiratory Diseases a
Externí odkaz:
https://doaj.org/article/d2d5e799b4e448af8c6a1a9d297a5e90
Autor:
Eun hee Lee, Eun-ju Lee, Hee jeong Kim, An soo Jang, Eun suk Koh, Soo-taek Uh, Yong hoon Kim, Sung-woo Park, Choon-sik Park
Publikováno v:
PLoS ONE, Vol 8, Iss 2, p e55827 (2013)
The inhalation of silica particles induces silicosis, an inflammatory and fibrotic lung disease characterized by the early accumulation of macrophages and neutrophils in the airspace and subsequent appearance of silicotic nodules as a result of progr
Externí odkaz:
https://doaj.org/article/7902e5a6c55f4fb5844f1ff9bb51ef77
Autor:
Jeong-Hyun Kim, Hyun Sub Cheong, Jong Sook Park, An-Soo Jang, Soo-Taek Uh, Yong-Hoon Kim, Mi-Kyeong Kim, Inseon S Choi, Sang Heon Cho, Byoung Whui Choi, Joon Seol Bae, Choon-Sik Park, Hyoung Doo Shin
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e71958 (2013)
Immunoglobulin E (IgE) is one of the central players in asthma and allergic diseases. Although the serum IgE level, a useful endophenotype, is generally increased in patients with asthma, genetic factors influencing IgE regulation in asthma are still
Externí odkaz:
https://doaj.org/article/32dc77340c3f4b8699a93f9e85988af6
Fatty acid binding protein 1 is related with development of aspirin-exacerbated respiratory disease.
Autor:
Tae-Hoon Kim, Ji-Yeon Lee, Jong-Sook Park, Sung-Woo Park, An-Soo Jang, Jae-Yong Lee, Jang-Yul Byun, Soo-Taek Uh, Eun-Suk Koh, Il Yup Chung, Choon-Sik Park
Publikováno v:
PLoS ONE, Vol 6, Iss 8, p e22711 (2011)
Aspirin-exacerbated respiratory disease (AERD) refers to the development of bronchoconstriction in asthmatics following the ingestion of aspirin. Although alterations in eicosanoid metabolites play a role in AERD, other immune or inflammatory mechani
Externí odkaz:
https://doaj.org/article/fb79242b18f94785a9fa1b3661a8e3d3
Autor:
Jeong-Hyun Kim, Byung-Lae Park, Hyun Sub Cheong, Joon Seol Bae, Jong Sook Park, An Soo Jang, Soo-Taek Uh, Jae-Sung Choi, Yong-Hoon Kim, Mi-Kyeong Kim, Inseon S Choi, Sang Heon Cho, Byoung Whui Choi, Choon-Sik Park, Hyoung Doo Shin
Publikováno v:
PLoS ONE, Vol 5, Iss 11, p e13818 (2010)
Aspirin-intolerant asthma (AIA) is a rare condition that is characterized by the development of bronchoconstriction in asthmatic patients after ingestion of non-steroidal anti-inflammatory drugs including aspirin. However, the underlying mechanisms o
Externí odkaz:
https://doaj.org/article/27a837697de245faaa6ae9dc67381883
Autor:
Jieun Kang, Man Pyo Chung, Moo Suk Park, In Jae Oh, Heung Bum Lee, Young Whan Kim, Jong Sun Park, Soo Taek Uh, Yun Seong Kim, Yangjin Jegal, Jin Woo Song
Publikováno v:
Frontiers in Pharmacology. 13
Background: Pirfenidone, an antifibrotic medication approved for the treatment of idiopathic pulmonary fibrosis (IPF), often requires dose reduction owing to adverse events. In this study, we evaluated if pirfenidone’s reduced dose has any impact o